Replies to post #778445 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

"And the only logical conclusion for all of you posting this over and over again is this: either you are not finished loading, or you are short. And if it’s the latter, then you are really going to regret it."

1 billion 🤣s

[fluteman]

Slave, you have humbly given IH credibility.

Desperately needed.

[exwannabe]

Flaskworks has been under MHRA review for over two years.

NWBO has not even ordered the actual EDEN devices that would be used.

I know Brits do things a bit different, but I doubt the MHRA is in charge of evaluating vapor-ware.

[dennisdave]

And just between us, are you afraid I’m right? Is that what this is? If you were confident I’m wrong, you’d leave it alone. But maybe your crew hasn’t finished accumulating yet and still needs to keep the price suppressed just a little longer. That would explain the sudden urgency to cast shade on logic that actually holds up

Your simplicity on full display. I have been invested in this turd way longer than you buddy, I own more NWBO shares than you. The "if you try to challenge me on my fantasy assumptions, then you are short" has been tried so many times here. Between you and me shorty, if that is your best argument, then you really are desperate. I personally think that you are a short suppling BS pump nonsens to your gullible audience, then selling before it turns out to you hopium fans that you are a full of s@%it.

[FeMike]

Once the draft SmPC is issued by MHRA, NICE can accept the submission. If NWBO has not submitted to NICE as of July 15, then logically, they had not yet received the draft.

Still refusing to acknowledge the indisputable FACT that you are wrong about the "draft"?

The draft is done, Slave. NWBO doesn't receive the draft, they generate it and give it to the MHRA. The MHRA reviews the draft and deploys the final label at the end of the process. The draft, which NWBO already has AS A MATTER OF FACT because they are the ones that made it as part of the required package for submitting an MAA, is already complete, in hand and ready to submit to NICE.

Why the draft, along with the entire evidence package, hasn't been submitted to NICE is the real mystery. But it has nothing to with the MHRA being in the labeling phase and NWBO waiting on a draft label which, again, is a regulatory impossibility.

Keep acting like you know stuff.

[dennisdave]

here is what you state as facst but are not facts

That the draft SmPC wasn’t issued by July 15 is based solely on NICE’s statement that NWBO hadn’t submitted their evidence yet.
That’s an inference, not a fact. NWBO could be waiting for a final SmPC, or for other internal alignment before submitting.

That MHRA entered the labeling phase around July 16–20
Again, inferred, not confirmed. MHRA doesn’t publish phase transitions. The start of labeling is opaque unless the company discloses it.

That Flaskworks validation and QP sign-off are already resolved
There is no public documentation confirming Flaskworks is approved as a Qualified Point-of-Care site under the new SI 87 framework. Operating “under SI 87” doesn’t necessarily mean full MHRA validation of Flaskworks for commercial use.

That 2–4 weeks is the full expected labeling duration
Possible, but not guaranteed. Some ATMPs require longer labeling discussions, especially if manufacturing or administration protocols are complex (e.g., EDEN units with decentralized QP oversight).

That the company and MHRA are fully aligned and moving without strategic delay
This ignores the potential for alignment with NICE timelines, IFR funding protocols, or broader health system negotiations.

and these are just on top of my head. No go back to your mom's basement

[joeycav11]

Remember when the shorts know that a treatment wont be approved they run the price up before the binary event.They pump up the potential and write positive news articles.
All the while taking short positions.
Here we have the opposite occurring.
Hope this gives some reassurance to weary longs